Protherics PLC announces Issue of Shares

CHESHIRE, UK , the international biopharmaceutical company focused on critical care and cancer, announces that the Company has today issued 1,741,911 ordinary shares pursuant to the MacroMed Acquisition Agreement ("Agreement") approved by shareholders at the Company's Extraordinary General Meeting held on 3 January 2007 and details of which were contained in the Company's announcement dated 7 December 2006. Under the terms of the Agreement 10% of the ordinary shares issuable upon the acquisition of MacroMed Inc. were held back for a period of 18 months from the date of the Acquisition and have become issuable on the basis that no claims against the MacroMed vendors have arisen over that period. Accordingly, application has today been made to the UK Listing Authority of the London Stock Exchange for the listing of 1,741,911 ordinary shares of 2p each in the Company. The Shares will rank equally with the existing issued ordinary shares of the Company and are expected to be admitted to the Official List and commence trading on or around 9 July 2008. Following admission of these ordinary shares, the Company's issued share capital will be 342,159,034 ordinary shares. / Ends / For further information please contact: Protherics Nick Staples, Director of Corporate Affairs [phone] Julie Vickers, Company Secretary [phone] Financial Dynamics - press enquiries London: Ben Atwell, Lara Mott [phone] New York: John Capodanno, Jonathan Birt [phone] Or visit www.protherics.com This information is provided by RNS The company news service from the London Stock Exchange END

Contacts: RNS Customer Services 0044-207797-4400 Email Contact http://www.rns.com